 LA JOLLA, Calif., Feb. 04, 2021 GLOBE NEWSWIRE -- Equillium, Inc. Nasdaq: EQ a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a securities purchase agreement with life science institutional investment funds managed by Decheng Capital, to purchase 4,285,710 units the Units from Equillium, with each Unit consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock. The purchase price per Unit is 7.00, priced above the market under Nasdaq rules. The warrants will have an exercise price of 14.00 per share, will be immediately exercisable, and will expire on the earlier of i the fifth anniversary of issuance, or ii the 15th calendar date following the date on which Equillium closes a financing raising a minimum of 25 million at a price per share of no less than 25.00. 